Clinical trials: Ritonavir
Human Immunodeficiency Virus
Special Investigation of Kaletra in Pregnant Women
This non-interventional, post-marketing observational study was conducted to obtain safety data from the use of lopinavir/ritonavir (Kaletra), in clinical practice, in pregnant women and their children in Japan.
- Trial name
- NCT01076985
- Testing
- Lopinavir/ritonavir (Kaletra)
- Where
- 5 sites in Japan
- Volunteers
- 24 people
- Sponsor
- Abbott
Antivirals/HIV
Drug Interaction Study
The purpose of this study is to evaluate the exposure of rifabutin (RIB) when administered with atazanavir and ritonavir (ATV/RTV)
- Trial name
- NCT00646776
- Testing
- Rifabutin, Rifabutin + Atazanavir + Ritonavir
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects (Study P04875)
Vicriviroc (vye-kri-VYE-rock) is an investigational drug (not yet approved by Government Regulatory Authorities for commercial use) that belongs to a new class of drugs, called CCR5 receptor blockers.
- Trial name
- NCT00551018
- Testing
- Vicriviroc, emtricitabine and tenofovir disoproxil fumarate
- Volunteers
- 218 people
- Sponsor
- Merck Sharp & Dohme LLC
COVID-19
A Study to Understand How the Use of Paxlovid Affected Healthcare Use in People With Pre-existing Conditions.
This is a cohort study that will include Paxlovid (nirmatrelvir-ritonavir) treatment eligible for people with a positive SARS-CoV-2 diagnostic test and at least one COVID-19 symptom.
- Trial name
- NCT07090486
- Testing
- nirmatrelvir-ritonavir
- Where
- United States
- Volunteers
- 14,000 people
- Sponsor
- Pfizer
Acute Herpes Zoster
A Study Investigating the Pharmacokinetics of FV-100 With and Without Ritonavir in Healthy Volunteers
This study is designed to evaluate the potential for a PK drug-drug interaction between FV-100 and ritonavir. The study is a single-center, open-label, randomized, 2-way crossover design in healthy volunteers.
- Trial name
- NCT02322957
- Testing
- FV-100
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- ContraVir Pharmaceuticals, Inc.
Covid-19
A Study of COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir in the Kingdom of Saudi Arabia
The aim of this study is to describe the baseline demographic, clinical characteristics, and Healthcare Resource Use (HCRU) of adult (≥18 years) COVID-19 patients who have been prescribed nirmatrelvir, ritonavir treatment.
- Trial name
- NCT06016556
- Testing
- nirmatrelvir, ritonavir
- Where
- 3 sites in Saudi Arabia
- Volunteers
- 250 people
- Sponsor
- Pfizer
Healthy
Effects of TPV/r on the Pharmacokinetics of Carbamazepine in Healthy Adult Volunteers
Study to assess the steady-state pharmacokinetics of carbamazepine (CBZ) at 200 mg or 100 mg twice daily, depending on tolerability, and administered alone and in combination with tipranavir/ritonavir (TPV/r) after a single dose…
- Trial name
- NCT02253849
- Testing
- Carbamazepine, Tipranavir, Ritonavir
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
HIV Infections
Tipranavir and Ritonavir vs. Saquinavir and Ritonavir Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 Patients
Objectives of the study were to evaluate the efficacy and safety of two different doses of tipranavir (TPV) in combination with ritonavir (TPV/r) compared with a standard dual PI combination of saquinavir (SQV) and ritonavir…
- Trial name
- NCT02239835
- Testing
- Tipranavir (TPV) low dose, Tipranavir (TPV) high dose, Ritonavir low dose
- Volunteers
- 79 people
- Sponsor
- Boehringer Ingelheim
Healthy
Effect of Different Boosting Agents on Pharmacokinetics of BILR 355 BS Dissolved in Polyethylene Glycol 400 (PEG 400) in Healthy Male Volunteers
Assessment of the effect of different boosting agents on pharmacokinetics of a single dose of BILR 355 BS dissolved in PEG 400
- Trial name
- NCT02257008
- Testing
- BILR 355 BS, Grapefruit juice, Nelfinavir
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Chronic Hepatitis c Genotype 1
Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1
Multicenter, open-label, phase II safety and efficacy study of all-oral combination of narlaprevir/ritonavir and sofosbuvir in Treatment-naïve Patients with Chronic Hepatitis C Genotype 1.
- Trial name
- NCT04246723
- Testing
- Narlaprevir, Ritonavir, Sofosbuvir
- Where
- 5 sites in Russia
- Volunteers
- 85 people
- Sponsor
- R-Pharm
Infection, Human Immunodeficiency Virus
Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults.
GSK has in-licensed a novel NNRTI-class candidate (GSK2248761, IDX12899) for the treatment of subjects with HIV-1 infection from Idenix Pharmaceuticals.
- Trial name
- NCT00945282
- Testing
- GSK2248761, Lopinavir/ritonavir, HAART
- Where
- Argentina
- Volunteers
- 8 people
- Sponsor
- ViiV Healthcare
2019 Novel Coronavirus Pneumonia
Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia
the investigators conduct a randomized, open-label trial to evaluate and compare the safety and efficacy of Xiyanping injection in patients with 2019-nCoV pneumonia.
- Trial name
- NCT04275388
- Testing
- Xiyanping injection, Lopinavir / ritonavir, alpha-interferon nebulization,Abidor Hydrochloride
- Volunteers
- 426 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
HIV, Tuberculosis
A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects
The purpose of this study is to study the safety, tolerability and pharmacokinetics of rifabutin dosing with lopinavir/ritonavir tablets in healthy volunteers.
- Trial name
- NCT00743470
- Testing
- lopinavir/ritonavir, rifabutin
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Abbott
Infection, Human Immunodeficiency Virus
Single and Repeated Dose Escalation Study of GSK2838232
GSK2838232 is a Human Immunodeficiency Virus (HIV) maturation inhibitor being developed for the treatment of HIV in combination with other antiretroviral therapy (ART).
- Trial name
- NCT02795754
- Testing
- GSK2838232 PIB, GSK2838232 IR1, GSK2838232 IR2
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
A Study to Assess the Effect of Ritonavir on the Single-Dose Pharmacokinetics of JNJ-61393215 in Healthy Participants
The primary purpose of this study is to assess the effect of ritonavir, on the single-dose pharmacokinetics (PK) of JNJ-61393215 in healthy participants.
- Trial name
- NCT03593954
- Testing
- JNJ-61393215, Ritonavir
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV
The goal of this clinical study is to learn more about the safety and dosing of study drugs, cobicistat-boosted Atazanavir (ATV/co), cobicistat-boosted darunavir (DRV/co) and emtricitabine/tenofovir alafenamide (F/TAF), in…
- Trial name
- NCT02016924
- Testing
- ATV, DRV, Cobicistat
- Where
- 23 sites in United States, Argentina and 5 more
- Volunteers
- 133 people
- Sponsor
- Gilead Sciences
Human Immunodeficiency Virus Infection
Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets)
Both twice-a-day (BID) and once-a-day (QD) dosing are approved in Europe for the protease inhibitor lopinavir/ritonavir (LPV/r; Kaletra®).
- Trial name
- QD-Kapital (NCT01383005)
- Where
- 20 sites in Spain
- Volunteers
- 97 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Healthy
Effects of Tipranavir (With Ritonavir) Capsule and Liquid Formulation on Cytochrome P450 and P-glycoprotein Activity in Healthy Volunteers
Primary: To quantify the influence of single-dose and steady-state tipranavir/ritonavir 500/200 mg on intestinal and hepatic cytochrome P450 (CYP) and P-glycoprotein (P-gp) biomarkers, as a means of predicting drug interactions.
- Trial name
- NCT02243553
- Testing
- Tipranavir capsule, Tipranavir solution, Ritonavir capsule
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Pharmacokinetic Interaction Between TRUVADA™ and BILR 355 BS Plus Ritonavir in Healthy Volunteers
Study to determine the pharmacokinetic effect of BILR 355 + ritonavir® on TRUVADA and TRUVADA on BILR 355
- Trial name
- NCT02253901
- Testing
- BILR 355 BS, Ritonavir, TRUVADA
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19)
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People with Weakened Immune Systems or at Increased Risk for Poor Outcomes who are Hospitalized Due to Severe COVID-19
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19), Immunocompromised, Hospitalization
- Trial name
- EPIC-HOS (NCT05545319)
- Testing
- Nirmatrelvir, Ritonavir
- Where
- 11 sites in United States, Bulgaria
- Sponsor
- Pfizer